Trial Profile
A study of the safety and toxicity of the combination of zoledronic acid, fluvastatin and everolimus given to patients with advanced cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Jun 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Fluvastatin; Zoledronic acid
- Indications Solid tumours
- Focus Adverse reactions
- 04 Jun 2013 New trial record